Every newborn child should be screened for congenital adrenal hyperplasia (CAH) and positive results should be followed by testing, according to a new clinical practice guideline from the Endocrine Society on the diagnosis and treatment of the condition.
Every newborn child should be screened for congenital adrenal hyperplasia (CAH) and positive results should be followed by testing, according to a new clinical practice guideline from the Endocrine Society on the diagnosis and treatment of the condition.
The guideline was recently published in the Journal of Clinical Endocrinology & Metabolism (2010; 95:4133-60).
"If CAH is not recognized and treated, both girls and boys undergo rapid postnatal growth and early sexual development or, in more severe cases, neonatal salt loss and death," said Phyllis Speiser, MD, of Cohen Children’s Medical Center, New Hyde Park, NY, and chair of the task force that developed the guideline. "We recommend that every newborn be screened for CAH and that positive results be followed up with confirmatory tests."
Other recommendations in the guideline include the following:
Among the organizations endorsing the guidelines are the American Academy of Pediatrics and the Society for Pediatric Urology.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.